Avalo Therapeutics, Inc. (AVTX)
| Market Cap | 414.01M +51.7% |
| Revenue (ttm) | 59,000 -69.3% |
| Net Income | -88.65M |
| EPS | -2.58 |
| Shares Out | 57.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,273,212 |
| Open | 7.07 |
| Previous Close | 7.27 |
| Day's Range | 6.88 - 7.56 |
| 52-Week Range | 6.53 - 24.27 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | 34.80 (+386.03%) |
| Earnings Date | Nov 5, 2026 |
About AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1β-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1β, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Financial Performance
In 2025, Avalo Therapeutics's revenue was $59,000, a decrease of -86.62% compared to the previous year's $441,000. Losses were -$78.26 million, 122.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for AVTX stock is "Strong Buy." The 12-month stock price target is $34.8, which is an increase of 386.03% from the latest price.
News
Avalo Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026
LOTUS showed ~43% HiSCR75 in both abdakibart arms, with consistent efficacy and no serious infections or clinically significant neutropenia. Phase III enrollment is targeted for early 2027, with HS top-line data expected in 2029; AVTX-010 is planned for clinic entry in H1 2027.
Avalo Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
LOTUS showed consistent efficacy across dose regimens and biologic-exposure groups, supporting a proposed 600/300 mg Phase III dose. Cash of $462M at end-September is expected to fund Phase III top-line in 2029 and AVTX-010’s planned 2027 clinical entry.
Avalo Therapeutics price target lowered to $20 from $22 at Wedbush
Wedbush lowered the firm’s price target on Avalo Therapeutics (AVTX) to $20 from $22 and keeps an Outperform rating on the shares after the company reported third quarter financials ahead…
Avalo Therapeutics price target lowered to $24 from $29 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Avalo Therapeutics (AVTX) to $24 from $29 and keeps a Buy rating on the shares.
Avalo Therapeutics files automatic mixed securities shelf
08:32 EST Avalo Therapeutics (AVTX) files automatic mixed securities shelf
Avalo Therapeutics reports Q3 EPS (34c), consensus (55c)
“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa,” said Garry Neil, Chief Executive Officer of Avalo. “The efficacy a...
Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting anti-IL-...
Avalo Therapeutics Quarterly report: Q3 2026
Avalo Therapeutics has published its Q3 2026 quarterly earnings report on November 5, 2026.
Avalo Therapeutics Earnings release: Q3 2026
Avalo Therapeutics released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Avalo Therapeutics Slides: Corporate presentation
Avalo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Avalo Therapeutics to Participate in Upcoming Investor Conferences
WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immun...
Avalo Therapeutics price target lowered to $16 from $35 at Oppenheimer
Oppenheimer lowered the firm’s price target on Avalo Therapeutics (AVTX) to $16 from $35 and keeps an Outperform rating on the shares.
Avalo Therapeutics price target lowered to $22 from $34 at Wedbush
Wedbush lowered the firm’s price target on Avalo Therapeutics (AVTX) to $22 from $34 and keeps an Outperform rating on the shares. The firm believes topline results from the Phase…
Avalo Therapeutics downgraded to Neutral at Guggenheim after AbbVie data
As previously reported, Guggenheim analyst Yatin Suneja downgraded Avalo Therapeutics (AVTX) to Neutral from Buy and removed the firm’s prior price target after AbbVie’s (ABBV) Phase 3 INTREPID study ...
Avalo Therapeutics price target lowered to $10 from $58 at BTIG
BTIG analyst Julian Harrison lowered the firm’s price target on Avalo Therapeutics (AVTX) to $10 from $58 and keeps a Buy rating on the shares. The Phase 3 INTREPID study…
Avalo Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Avalo Therapeutics (AVTX) to Neutral from Buy without a price target Lutikizumab’s eight point HiSCR75 benefit “substantially weakens” the case for Interleukin-1 in hidraden...
Avalo Therapeutics downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded Avalo Therapeutics (AVTX) to Neutral from Buy and removed the firm’s prior price target.
Avalo Therapeutics trading resumes
09:36 EDT Avalo Therapeutics (AVTX) trading resumes
Avalo Therapeutics trading halted, volatility trading pause
09:31 EDT Avalo Therapeutics (AVTX) trading halted, volatility trading pause
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
WAYNE, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immu...
Avalo Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum
Abdakibart demonstrated strong efficacy and safety in phase II for HS, supporting advancement to phase III in 2027. The company is expanding its IL-1 beta franchise with AVTX-010 and maintains a robust cash position to fund development through 2029.
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
WAYNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immu...
Avalo Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Abdakibart met LOTUS phase II endpoints, with week-16 HiSCR75 of 42.2% and 42.9% versus 25.6% for placebo. Phase III and an AVTX-010 IND were planned for H1 2027, supported by $472M in end-June cash and investments.
Avalo Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A clinical-stage biotech is advancing its potent anti-IL-1 beta antibody, abdakibart, into phase III for HS after strong phase II results and positive physician feedback. Expansion plans include a long-acting version and new indications in dermatology and rheumatology, with robust financial backing and a focus on differentiated dosing and device strategy.
Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim
Guggenheim lowered the firm’s price target on Avalo Therapeutics (AVTX) to $48 from $50 and keeps a Buy rating on the shares.